This Undiscovered Biotech Stock Has Quintupled in a Year and Just Hit New Highs

Core Insights - Burning Rock Biotech (BNR) is valued at $209 million and specializes in next-generation sequencing technology for precision oncology, focusing on therapy selection testing for late-stage cancer patients and early cancer detection [1] - The stock has shown exceptional performance, gaining 405% over the past year and hitting a 2-year high of $23.45 [4][5] - BNR has a 100% "Buy" opinion from Barchart, with a recent trading price of $21.58 and a 50-day moving average of $11.20 [6] Technical Performance - BNR has experienced significant technical momentum, with a Weighted Alpha of +82.77 and a Relative Strength Index (RSI) of 75.84 [6] - The stock gained 107.05% since the Trend Seeker signaled a new "Buy" on October 22 [2] - In the last month, BNR has made 7 new highs and gained 64.3% [6] Market Position - Burning Rock Biotech is based in Guangzhou, China, and operates in the precision oncology sector [1] - The company is considered highly speculative and risky despite its strong technical indicators [5]